Arrhythmia Detection After MI (AID MI)

Arrhythmia Detection After Myocardial Infarction Trial

Patients post acute myocardial infarction (AMI) have a high risk of mortality but the use of an implantable defibrillator in the early aftermath of an AMI has not been shown to improve patients' survival. The VEST trial recently demonstrated an improved overall survival in post AMI patients with the use of a wearable defibrillator. The same improvement was not demonstrated for the risk of sudden cardiac death. Monitoring patients after AMI using an implantable cardiac monitor (ICM) may document findings that can impact patient management and eventually improve their outcomes. We are therefore conducting the AID MI trial to examine the impact of ICM on patient management in the post AMI setting.

Study Overview

• Status: Recruiting
• Conditions: Acute Myocardial Infarction
• Intervention / Treatment: Other: Standard of Care; Device: ICM Implantation

Detailed Description

Patients who have ventricular tachycardia or fibrillation at least 48 hours after an acute myocardial infarction (AMI) have a higher risk of sudden cardiac death. Current guidelines recommend that for primary prevention of sudden cardiac death, patients with left ventricular ejection fraction (LVEF) ≤ 35% should wait at least 40 days post-AMI or 90 days post revascularization prior to receiving an implantable cardioverter defibrillator (ICD). This period of time potentially leaves a vulnerable population without protection from sudden cardiac death (SCD).

The landmark MADIT I and MADIT II trials demonstrated that ICD therapy was associated with significantly improved survival in patients with ischemic cardiomyopathy at any interval of time. The DINAMIT study demonstrated that ICD placement less than 40 days after AMI had a reduction in arrhythmic mortality at the cost of an increase in non-arrhythmic mortality. Results from these and other studies suggest that the risk of SCD after AMI may be time-dependent and that patients at increased risk for SCD are also at increased risk for death from other causes. Thus, there is a need for additional studies to identify subsets of patients with arrhythmias that may benefit from other therapeutic interventions such as ablations, anti-arrhythmic medications, implantable cardiac devices, or other therapies.

The CARISMA study was the first study to document the incidence of cardiac arrhythmias in post-AMI patients with left ventricular dysfunction (LVEF≤40%) using an implantable loop recorder. Results showed high incidences of arrhythmias such as new-onset AF (27.6%) and high-degree AV block (9.8%). Subsequent studies showed that these arrhythmias were associated with increased risk of major cardiovascular events such as heart failure, ventricular tachyarrhythmias, stroke, reinfarction, or cardiac death.

It has been shown that utilizing remote monitoring as part of clinical care in patients with cardiac implantable electronic devices is associated with improved all-cause survival; the magnitude of survival increases with the degree of adherence to remote monitoring and the timeliness to enroll and activate in remote monitoring shortly after device implantation.

These studies suggest the need for further investigation and evaluation of acute and long-term cardiac monitoring in post-AMI patients, in an effort to identify patients at greatest risk, inform clinical decision making and potentially reduce the risk of all-cause mortality. In addition, the ability to remotely monitor patients may minimize the time to diagnosis and enable early intervention in this patient population.

• Study Type: Interventional
• Enrollment (Estimated): 200
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Melissa Enlow; Phone Number: 412-647-1582; Email: enlowms@upmc.edu
• Study Contact Backup: Name: Samir F Saba, MD; Phone Number: 412 647 2695; Email: sabas@upmc.edu

Study Locations

• United States
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15213
      • Recruiting
      • UPMC Presbyterian Hospital
      • Contact: Eric Pasquantonio; Phone Number: 14126478210; Email: pasquantonioej@upmc.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults, age 18 years or older
• AMI (STEMI and NSTEMI)
• Willing to give written informed consent
• Expected discharge from hospital within 7 days of AMI
• Willing to receive ICM insertion within 21 days of index AMI

Exclusion Criteria:

• Existing pacemaker, ICD, ICM, or any other implantable cardiac electronic device
• Pregnant
• Index AMI was more than 21 days
• Unwilling/cannot insert ICM within 21 days post AMI
• Planned ICD implant, planned CABG or any open-heart surgery (e.g. for severe valvular disease)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Control; Post-AMI patients in this arm will receive standard of care	Other: Standard of Care; Routine monitoring of post AMI patient with clinic visits; Other Names: Control
Experimental: ICM; Post-AMI patients in this arm will receive standard of care and an ICM	Device: ICM Implantation; Implantation of ICM through small incision (2 mm) under the skin; Other Names: ICM

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes to patient management	Incidence (frequency) of cardiac arrhythmias (bradyarrhythmia, tachyarrhythmia, pause, etc…) that lead to actionable treatment change	90 days post AMI
Time to diagnosis and/or treatment of cardiac arrhythmia	days post randomization	90 days post AMI

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes to patient management	Incidence (frequency) of cardiac arrhythmias (bradyarrhythmia, tachyarrhythmia, pause, etc…) that lead to actionable treatment change	24 months
Mortality	all-cause mortality	at 90 days
Mortality	All-cause mortality	at 24 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Depression and Anxiety Scale	Hospital Anxiety and Depression Scale (HADS) Minimum 0 and maximum 21 0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case)	at 90 days
Depression and Anxiety Scale	Hospital Anxiety and Depression Scale (HADS) Minimum 0 and maximum 21 0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case)	at 24 months
Physical and Mental Health	PROMIS-29 scale Scale ranges from 29 to 145 with a higher number indicating better physical and mental health	at 90 days
Physical and Mental Health	PROMIS-29 scale Scale ranges from 29 to 145 with a higher number indicating better physical and mental health	at 24 months

Collaborators and Investigators

• Sponsor: Samir Saba
• Collaborators: Abbott
• Investigators: Principal Investigator: Samir F Saba, MD, University of Pittsburgh Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): August 9, 2022
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026

Study Registration Dates

• First Submitted: September 28, 2021
• First Submitted That Met QC Criteria: September 28, 2021
• First Posted (Actual): October 11, 2021

Study Record Updates

• Last Update Posted (Actual): July 16, 2025
• Last Update Submitted That Met QC Criteria: July 10, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Necrosis; Myocardial Ischemia; Ischemia; Myocardial Infarction; Infarction
• Other Study ID Numbers: STUDY21060027

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Publication of protocol, methods, results in aggregates
• IPD Sharing Time Frame: 1 year after publication of the mainmanuscript
• IPD Sharing Access Criteria: Submit request to PI Only de-identified data will be shared
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes